Skip to main content
. Author manuscript; available in PMC: 2015 May 11.
Published in final edited form as: Biol Blood Marrow Transplant. 2014 Oct 15;21(2):202–224. doi: 10.1016/j.bbmt.2014.10.003

Table 1.

Clinical Research Questions Identified at SOSS

First SOSS

  1. Bone marrow versus peripheral blood for matched sibling HCT

  2. Bone marrow versus peripheral blood for matched unrelated donor HCT

  3. Single versus double cord blood transplantation

  4. Utility of T cell depletion of allogeneic bone marrow

  5. Utility of sirolimus added to conventional GVHD prophylaxis

  6. Allogeneic transplantation versus chemotherapy for older patients with AML

SOSS2

  1. Chemotherapy versus unrelated donor HCT for patients with high-risk AML

  2. Full intensity versus reduced intensity conditioning for patients with AML

  3. Chemotherapy + dasatinib versus allogeneic HCT for patients with Ph+ ALL

  4. Reduced intensity allogeneic HCT for patients with very high-risk CLL

  5. Reduced intensity allogeneic HCT for T cell lymphoma

  6. Reduced intensity allogeneic HCT in children with hemophagocytic lymphohistiocytosis

  7. Autologous HCT for refractory Crohn’s disease

  8. Use of viral specific T cells to treat adenoviral infections

  9. Development of calcineurin-free regimens to treat chronic GVHD

  10. Comparison of allogeneic HCT versus chemotherapy after autologous HCT for patients with MM

  11. Comparison of peritransplantation stress management interventions

Ph+ indicates philadelphia chromosome positive; CLL, chronic lymphocytic leukemia.